Your browser doesn't support javascript.
loading
Nitric oxide levels in HIV-infected, untreated patients and HIV-infected patients receiving antiretroviral therapy.
Soccal, Renata Mezomo; de Carvalho, José Antonio Mainardi; Bochi, Guilherme Vargas; Moresco, Rafael Noal; da Silva, José Edson Paz.
Afiliação
  • Soccal RM; Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil; Hospital Universitário de Santa Maria, RS, Brazil.
  • de Carvalho JA; Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil; Hospital Universitário de Santa Maria, RS, Brazil.
  • Bochi GV; Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
  • Moresco RN; Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil; Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
  • da Silva JE; Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil. Electronic address: jepazdasilva@gmail.com.
Biomed Pharmacother ; 79: 302-7, 2016 Apr.
Article em En | MEDLINE | ID: mdl-27044841
The role of nitric oxide (NO) in HIV infection is ambiguous; controversy exists around whether the levels of serum NO are increased or decreased in HIV-infected patients. Thus, it is necessary to reassess NO levels in HIV-infected patients. The aim of this study was to investigate the nitrite/nitrate metabolite (NOx) levels in HIV-infected untreated patients and in HIV-infected patients receiving highly active antiretroviral therapy (HAART), compared with HIV-uninfected individuals (control group). The HIV-infected patients enrolled in this study had been receiving HAART for at least 6 months (HIV-treated) or had not received HAART for at least 6 months (HIV-untreated group). New recommendations encourage initiating treatment in HIV-infected adults at a CD4 cell count of 500 cells/mm(3) or less. We also investigated whether levels of NOx were associated with immunophenotypic characteristic of HIV-infected patients. Our results showed a statistically significant increase in NOx levels in the HIV-untreated group (164.0 ± 166.6 µmol/L), compared with both the control (98.9 ± 59.4 µmol/L) and HIV-treated group (71.7 ± 53.3 µmol/L). Multiple regression analysis showed that the differences in NOx level were independent of gender, liver enzyme level, lipid measurement, and hematological parameters. In addition, a lower CD4/CD8 ratio was associated with higher NOx levels in HIV-infected patients. The results further revealed that NOx levels were increased in HIV infection, and that derangement of immune system function was associated with increased NO levels. The levels of NOx were found to decline with the use of HAART, which may contribute to cardiovascular disease in HIV-infected patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Terapia Antirretroviral de Alta Atividade / Óxido Nítrico Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Terapia Antirretroviral de Alta Atividade / Óxido Nítrico Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: França